Literature DB >> 27585476

A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.

Michaël Philippe1,2, Michael Neely3, Yves Bertrand4, Nathalie Bleyzac4,5, Sylvain Goutelle5,6,7.   

Abstract

The traditional approach for model-based initial dosing is based on the use of a single vector of typical population parameters for targeting a specific exposure. This approach is theoretically ill-suited for targeting a range of exposure. The objective of this work was to develop a general approach for optimal (OPT) targeting of a drug exposure interval. After methodological purposes, we applied our method to the busulfan case. We used a nonparametric population pharmacokinetic model of intravenous busulfan to estimate the individual pharmacokinetic parameters of 163 bone marrow-transplanted children. Then, an array of 151 doses of busulfan ranging from 0.5 to 2 mg/kg was simulated a priori in each patient. For each dose, 29 possible busulfan plasma concentration profiles, corresponding to the nonparametric prior, each associated with a probability, were obtained. The multiple-model-based, OPT dose was identified as the dose maximizing the a priori probability of achieving the busulfan target area under the concentration-time curve (AUC). Two AUC targets were considered: 900-1500 (conventional) or <1500 µM min-1. Finally, the OPT dose was individually simulated in each patient. We compared the ability of this method to achieve the target exposure interval with that of three other traditional model-based methods and one based on the non-parametric approach. When targeting the busulfan conventional AUC range, the OPT dose provided better attainment than the best of the three other methods after one dose (82.2 vs. 41.7 %, p < 0.005), two doses (79.1 vs. 65.0 %, p < 0.005), and at the end of therapy (80.4 vs. 76.7 %, p < 0.42). The approach provided a balanced distribution between under- (10.4 %) and overexposure (9.2 %), while other approaches showed higher rates of underexposure (≥19 %). When targeting an AUC <1500 µM min, the OPT dose was successful in minimizing overexposure as 0 % of children showed simulated AUC >1500 µM min-1. Our approach has been designed to optimize the targeting of an exposure interval. When applied to busulfan in children, it outperformed the traditional model-based dosing approach, with earlier and better achievement of busulfan target AUC. The approach can be applied for OPT dosing of many drugs, when the target objective is an interval.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27585476     DOI: 10.1007/s40262-016-0448-6

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  43 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

2.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

Authors:  W E Evans; M V Relling; J H Rodman; W R Crom; J M Boyett; C H Pui
Journal:  N Engl J Med       Date:  1998-02-19       Impact factor: 91.245

3.  Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.

Authors:  Reta Malär; Fredrik Sjöö; Katharina Rentsch; Moustapha Hassan; Tayfun Güngör
Journal:  Pediatr Transplant       Date:  2011-07-08

4.  Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Authors:  M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

5.  Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

Authors:  Jeannine S McCune; Meagan J Bemer; Jeffrey S Barrett; K Scott Baker; Alan S Gamis; Nicholas H G Holford
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

6.  The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.

Authors:  Hundie Tesfaye; Romana Branova; Eva Klapkova; Richard Prusa; Daniela Janeckova; Petr Riha; Petr Sedlacek; Petra Keslova; Josef Malis
Journal:  Ann Transplant       Date:  2014-05-09       Impact factor: 1.530

7.  Association of busulfan area under the curve with veno-occlusive disease following BMT.

Authors:  S P Dix; J R Wingard; R E Mullins; I Jerkunica; T G Davidson; C E Gilmore; R C York; L S Lin; S M Devine; R B Geller; L T Heffner; C D Hillyer; H K Holland; E F Winton; R Saral
Journal:  Bone Marrow Transplant       Date:  1996-02       Impact factor: 5.483

8.  Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.

Authors:  Michael Neely; Roger Jelliffe
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126

9.  I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.

Authors:  L Nguyen; D Fuller; S Lennon; F Leger; C Puozzo
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

10.  Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.

Authors:  Michael Neely; Michael Philippe; Teresa Rushing; Xiaowei Fu; Michael van Guilder; David Bayard; Alan Schumitzky; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Ther Drug Monit       Date:  2016-06       Impact factor: 3.681

View more
  4 in total

1.  Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Kana Mizuno; Min Dong; Tsuyoshi Fukuda; Sharat Chandra; Parinda A Mehta; Scott McConnell; Elias J Anaissie; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

2.  Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients.

Authors:  Clément Boidin; Laurent Bourguignon; Sabine Cohen; Claire Roger; Jean-Yves Lefrant; Jason A Roberts; Bernard Allaouchiche; Alain Lepape; Arnaud Friggeri; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.

Authors:  Rajith K R Rajoli; David J Back; Steve Rannard; Caren Freel Meyers; Charles Flexner; Andrew Owen; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

Review 4.  Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Khalil Ben Hassine; Madeleine Powys; Peter Svec; Miroslava Pozdechova; Birgitta Versluys; Marc Ansari; Peter J Shaw
Journal:  Front Pediatr       Date:  2021-12-10       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.